Welcome to our dedicated page for SAB BIOTHERAPEUTICS SEC filings (Ticker: SABSW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SAB Biotherapeutics filings document a clinical-stage biopharmaceutical issuer focused on SAB-142 and human immunoglobulin G therapies for autoimmune disease. Recent Form 8-K disclosures cover Regulation FD clinical presentations for the SAB-142 HUMAN trial, other clinical data announcements, and a manufacturing services agreement for clinical and commercial supply of SAB-142.
The company’s proxy materials describe annual meeting matters, director elections, board governance, stockholder voting procedures, and executive-compensation disclosures. Its SEC record also identifies capital-structure items including common stock and warrants exercisable for common stock, along with risk and forward-looking disclosure tied to clinical development, regulatory approval, manufacturing, and financing needs.